MDHearing Volt vs Otofonix Groove

The MDHearing Volt is a budget-priced prescription hearing aid available for $397, earning a B grade with a SoundScore of 3.1/5 in our lab testing. This behind-the-ear, rechargeable device ranks #32 of 36 prescription hearing aids tested, placing it in the top 86% of its category. In our standardized testing, the Volt demonstrates excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. This represents a genuine strength, as the device remained stable under our challenge protocols without audible squealing or whistling. However, speech performance presents significant limitations: speech in quiet scored 1.8/5 (1.57 points below the category average of 3.32), while speech in noise scored 1.0/5 (0.96 points below the 1.96 average). Own-voice comfort measured 2.6/5, a mixed result that falls 0.15 points below the category average. Music streaming is notably limited at 0.0/5, scoring 2.64 points below the category average—users prioritizing phone streaming should consider alternatives. The Volt showed no improvement between Initial and Tuned fits, with both configurations yielding identical scores of 3.1/5. The MDHearing Volt may suit budget-conscious consumers who prioritize basic amplification and excellent feedback stability over speech clarity or streaming features. However, shoppers in this price range should note that alternatives like the RxEars Rxi offer substantially higher performance at similar pricing.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.